ArticleHypertension (Dallas, Tex. : 1979)2017
Functional TASK-3-Like Channels in Mitochondria of Aldosterone-Producing Zona Glomerulosa Cells.
Open access · bronzeAbstract read
In one paragraph
Article in Hypertension (Dallas, Tex. : 1979), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Downregulation of TASK-3 Channel Induces Senescence in Granulosa Cells of Bovine Cystic Ovarian Follicles.International journal of molecular sciences · 2024Article
- Redox Regulation of Mitochondrial Potassium Channels Activity.Antioxidants (Basel, Switzerland) · 2024Review
- TALK-1-mediated alterations of β-cell mitochondrial function and insulin secretion impair glucose homeostasis on a diabetogenic diet.Cell reports · 2024Article
- Advances in the Understanding of Two-Pore Domain TASK Potassium Channels and Their Potential as Therapeutic Targets.Molecules (Basel, Switzerland) · 2022Review
- Alternative Targets for Modulators of Mitochondrial Potassium Channels.Molecules (Basel, Switzerland) · 2022Review
- Mitochondrial ion channels in cardiac function.American journal of physiology. Cell physiology · 2021Review
- Routes for Potassium Ions across Mitochondrial Membranes: A Biophysical Point of View with Special Focus on the ATP-Sensitive KBiomolecules · 2021Review
- Ion Channel Function and Electrical Excitability in the Zona Glomerulosa: A Network Perspective on Aldosterone Regulation.Annual review of physiology · 2021Review
- TASK-1 and TASK-3 channels modulate pressure overload-induced cardiac remodeling and dysfunction.American journal of physiology. Heart and circulatory physiology · 2020Article
- Novel Potassium Channels in Kidney Mitochondria: The Hyperpolarization-Activated and Cyclic Nucleotide-Gated HCN Channels.International journal of molecular sciences · 2019Article
- The Potassium Channel Odyssey: Mechanisms of Traffic and Membrane Arrangement.International journal of molecular sciences · 2019Review
- The Biology of Normal Zona Glomerulosa and Aldosterone-Producing Adenoma: Pathological Implications.Endocrine reviews · 2018Review
- Mouse Models of Primary Aldosteronism: From Physiology to Pathophysiology.Endocrinology · 2017Article
- TALK-1 channels control β cell endoplasmic reticulum CaScience signaling · 2017Article
- Of Mice and Man and the Regulation of Aldosterone Secretion.Hypertension (Dallas, Tex. : 1979) · 2017Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Junlan YaoFrom the Departments of Pharmacology (J.Y., D.M., W.E.M., N.A.G., D.A.B., P.Q.B.) and Psychology (A.E.), University of Virginia School of Medicine, Charlottesville; Silverback Therapeutics, Inc, Seattle, WA (C.A.C.); and Department of Neuroscience, Merck & Co, Inc, West point, PA (V.P.S.).
David McHedlishviliFrom the Departments of Pharmacology (J.Y., D.M., W.E.M., N.A.G., D.A.B., P.Q.B.) and Psychology (A.E.), University of Virginia School of Medicine, Charlottesville; Silverback Therapeutics, Inc, Seattle, WA (C.A.C.); and Department of Neuroscience, Merck & Co, Inc, West point, PA (V.P.S.).
William E McIntireFrom the Departments of Pharmacology (J.Y., D.M., W.E.M., N.A.G., D.A.B., P.Q.B.) and Psychology (A.E.), University of Virginia School of Medicine, Charlottesville; Silverback Therapeutics, Inc, Seattle, WA (C.A.C.); and Department of Neuroscience, Merck & Co, Inc, West point, PA (V.P.S.).
Nick A GuagliardoFrom the Departments of Pharmacology (J.Y., D.M., W.E.M., N.A.G., D.A.B., P.Q.B.) and Psychology (A.E.), University of Virginia School of Medicine, Charlottesville; Silverback Therapeutics, Inc, Seattle, WA (C.A.C.); and Department of Neuroscience, Merck & Co, Inc, West point, PA (V.P.S.).
Alev ErisirFrom the Departments of Pharmacology (J.Y., D.M., W.E.M., N.A.G., D.A.B., P.Q.B.) and Psychology (A.E.), University of Virginia School of Medicine, Charlottesville; Silverback Therapeutics, Inc, Seattle, WA (C.A.C.); and Department of Neuroscience, Merck & Co, Inc, West point, PA (V.P.S.).
Craig A CoburnFrom the Departments of Pharmacology (J.Y., D.M., W.E.M., N.A.G., D.A.B., P.Q.B.) and Psychology (A.E.), University of Virginia School of Medicine, Charlottesville; Silverback Therapeutics, Inc, Seattle, WA (C.A.C.); and Department of Neuroscience, Merck & Co, Inc, West point, PA (V.P.S.).
Vincent P SantarelliFrom the Departments of Pharmacology (J.Y., D.M., W.E.M., N.A.G., D.A.B., P.Q.B.) and Psychology (A.E.), University of Virginia School of Medicine, Charlottesville; Silverback Therapeutics, Inc, Seattle, WA (C.A.C.); and Department of Neuroscience, Merck & Co, Inc, West point, PA (V.P.S.).
Douglas A BaylissFrom the Departments of Pharmacology (J.Y., D.M., W.E.M., N.A.G., D.A.B., P.Q.B.) and Psychology (A.E.), University of Virginia School of Medicine, Charlottesville; Silverback Therapeutics, Inc, Seattle, WA (C.A.C.); and Department of Neuroscience, Merck & Co, Inc, West point, PA (V.P.S.).
Paula Q BarrettFrom the Departments of Pharmacology (J.Y., D.M., W.E.M., N.A.G., D.A.B., P.Q.B.) and Psychology (A.E.), University of Virginia School of Medicine, Charlottesville; Silverback Therapeutics, Inc, Seattle, WA (C.A.C.); and Department of Neuroscience, Merck & Co, Inc, West point, PA (V.P.S.). pqb4b@virginia.edu.
Neoleukin Therapeutics (United States) · US
Funding
Two-Pore Domain Potassium Channels and Aldosterone SecretionR01HL089717 · NHLBI · UNIVERSITY OF VIRGINIA · PI BARRETT, PAULA Q, BAYLISS, DOUGLAS A. · 2008 to 2017
$3.4MMBF Bioscience and Zeiss Microscope System for Stereology and Tissue MorphologyS10RR026799 · NCRR · UNIVERSITY OF VIRGINIA · PI OKUSA, MARK DOUGLAS · 2010 to 2010
$278kNCRR NIH HHS S10 RR026799NHLBI NIH HHS R01 HL089717
Abstract
Ca
Indexed as
AldosteroneCells, CulturedHumansHyperaldosteronismMembrane Potential, MitochondrialMitochondriaPotassium Channels, Tandem Pore DomainZona GlomerulosaAldosteronePotassium Channels, Tandem Pore Domainaldosteronehyperaldosteronismion channelsmitochondriazona glomerulosa
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.